Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond–Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
25 September 2020
In the original version of this Article, in Table 1 the Year of HST for cases 3, 4, 15 and 25 was not shown. They now appear in Table 1 in the PDF and HTML versions of the Article.
14 October 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41409-020-01076-x
References
Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U. et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:859–76. https://doi.org/10.1111/j.1365-2141.2008.07269.x.
Vlachos A, Rosenberg PS, Atsidaftos E, Alter BP, Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119:3815–9. https://doi.org/10.1182/blood-2011-08-375972.
Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116:3715–23. https://doi.org/10.1182/blood-2010-02-251090.
Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia. Br J Haematol. 2019;184:123–33. https://doi.org/10.1111/bjh.15701.
de Latour RP, Peters C, Gibsons B, Strahm B, Lankester A, de Heredia CD. et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transpl. 2015;50:1168–72. https://doi.org/10.1038/bmt.2015.117.
Burroughs LM, Shimamura A, Talano JA, Domm JA, Baker KK, Delaney C. et al. Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transpl. 2017;23:1669–77. https://doi.org/10.1016/j.bbmt.2017.06.002.
Roy V, Perez WS, Eapen M, Marsh JC, Pasquini M, Pasquini R. et al. Bone marrow transplantation for diamond-blackfan anemia. Biol Blood Marrow Transpl. 2005;11:600–8. https://doi.org/10.1016/j.bbmt.2005.05.005.
Crazzolara R, Kropshofer G, Haas OA, Matthes-Martin S, Kager L. Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia. Haematologica. 2017;102:e73–e75. https://doi.org/10.3324/haematol.2016.157149.
Asquith JM, Copacia J, Mogul MJ, Bajwa RP. Successful use of reduced-intensity conditioning and matched-unrelated hematopoietic stem cell transplant in a child with Diamond-Blackfan anemia and cirrhosis. Pediatr Transpl. 2015;19:E157–159. https://doi.org/10.1111/petr.12547.
Ostronoff M, Florencio R, Campos G, Arruda S, Matias C, Florencio M, et al. Successful nonmyeloablative bone marrow transplantation in a corticosteroid-resistant infant with Diamond-Blackfan anemia. Bone Marrow Transpl. 2004;34:371–2. https://doi.org/10.1038/sj.bmt.1704592.
Mugishima H, Ohga S, Ohara A, Kojima S, Fujisawa K, Tsukimoto I. Hematopoietic stem cell transplantation for Diamond-Blackfan anemia: a report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology. Pediatr Transpl. 2007;11:601–7. https://doi.org/10.1111/j.1399-3046.2006.00616.x.
Fagioli F, Quarello P, Zecca M, Lanino E, Corti P, Favre C, et al. Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. Br J Haematol. 2014;165:673–81. https://doi.org/10.1111/bjh.12787.
Wang R, Yoshida K, Toki T, Sawada T, Uechi T, Okuno Y, et al. Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. Br J Haematol. 2015;168:854–64. https://doi.org/10.1111/bjh.13229.
Ikeda F, Yoshida K, Toki T, Uechi T, Ishida S, Nakajima Y, et al. Exome sequencing identified RPS15A as a novel causative gene for Diamond-Blackfan anemia. Haematologica. 2017;102:e93–e96. https://doi.org/10.3324/haematol.2016.153932.
Konno Y, Toki T, Tandai S, Xu G, Wang R, Terui K, et al. Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica. 2010;95:1293–9. https://doi.org/10.3324/haematol.2009.020826.
Ichimura T, Yoshida K, Okuno Y, Yujiri T, Nagai K, Nishi M, et al. Diagnostic challenge of Diamond-Blackfan anemia in mothers and children by whole-exome sequencing. Int J Hematol. 2017;105:515–20. https://doi.org/10.1007/s12185-016-2151-7.
Kuramitsu M, Sato-Otsubo A, Morio T, Takagi M, Toki T, Terui K, et al. Extensive gene deletions in Japanese patients with Diamond-Blackfan Anemia. Blood. 2012;119:2376–84. 8
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17. https://doi.org/10.1016/0002-9343(80)90380-0.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9. https://doi.org/10.1016/j.bbmt.2008.12.497.
Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, et al. Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. Bone Marrow Transpl. 2009;43:611–7. https://doi.org/10.1038/bmt.2008.372.
Ulirsch JC, Verboon JM, Kazerounian S, Guo MH, Yuan D, Ludwig LS, et al. The genetic landscape of Diamond-Blackfan Anemia. Am J Hum Genet. 2018;103:930–47. https://doi.org/10.1016/j.ajhg.2018.10.027.
Peffault de Latour R, Peters C, Gibson B, Strahm B, Lankester A, de Heredia CD, et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. Bone Marrow Transpl. 2015;50:1168–72. https://doi.org/10.1038/bmt.2015.117.
Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, Quevedo E, et al. Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective Cohort Study. Hematology. 1999;4:505–12. https://doi.org/10.1080/10245332.1999.11746478.
Kim H, Lee KH, Sohn SK, Jung CW, Joo YD, Kim SH, et al. Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia. Leuk Res. 2013;37:1241–7. https://doi.org/10.1016/j.leukres.2013.06.024.
Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403–9. https://doi.org/10.1038/bmt.2015.283.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024.
Acknowledgements
We thank all medical and co-medical staffs who participated in the treatment of DBA patients in Japan. This work was supported by a research grant from the Ministry of Health, Labor and Welfare of Japan (Research on Measures for Intractable Diseases) (19FC1005) and by Grant-in-aids for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI: 17K10093, 18K07868), from the Japan Agency for Medical Research and Development (AMED) (JP19cm0106501 and 15H05909), from the Japan Society for the Promotion of Science (JSPS) (JP19H05656), and from the Ministry of Education, Culture, Sports, Science and Technology (hp160219).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Koyamaishi, S., Kamio, T., Kobayashi, A. et al. Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond–Blackfan anemia. Bone Marrow Transplant 56, 1013–1020 (2021). https://doi.org/10.1038/s41409-020-01056-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-01056-1
This article is cited by
-
Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes
International Journal of Hematology (2022)
-
Conditioning agents
Reactions Weekly (2021)